Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Kynexis has raised $61.0M in total funding. The most recent round was Series A. The last funding was announced in November 2023.
Kynexis's investors include Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures.
Kynexis is headquartered in Naarden, The Netherlands.
Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Kynexis is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kynexis — Funding & Investors." VCBacked, November 7, 2023, https://www.vcbacked.co/company/kynexis. Accessed November 14, 2026.
VCBacked. (2023). Kynexis — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/kynexis
{{cite web |title=Kynexis — Funding & Investors |url=https://www.vcbacked.co/company/kynexis |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Kynexis? Request a listing update